Sun Pharmaceutical Industries Limited has received formal ‘no-objection’ letters from both the National Stock Exchange of India (NSE) and BSE Limited (BSE). These letters are in response to the company’s application for the reclassification of certain individuals from the ‘Promoter Group’ category to the ‘Public’ category. This move is in accordance with Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Approval for Reclassification
Sun Pharmaceutical Industries Limited announced on August 6, 2026, that it has secured essential ‘no-objection’ letters from both the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). These approvals pertain to the company’s request for the reclassification of specific individuals from the ‘Promoter Group’ status to the ‘Public’ category.
Compliance with SEBI Regulations
This reclassification is being undertaken in strict adherence to Regulation 31A of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously intimated its intention for this reclassification on May 14, 2026, with subsequent updates on May 22, 2026, and May 26, 2026. The no-objection letters are dated August 6, 2026.
Key Individuals Affected
The individuals involved in this reclassification, as detailed in the annexures from both NSE and BSE, include:
- Krishna Vrundavandas Valia
- Sudhir Vrundavandas Valia
- Raksha Sudhir Valia
The company has made copies of the no-objection letters available on its official website, www.sunpharma.com, and as attached annexures to this intimation. This disclosure is made to ensure compliance with the relevant SEBI Listing Regulations.
Source: BSE
